What is measurable residual disease (MRD) and why does it matter in AML care? Dr. David Sallman explains how this sensitive test can detect even very small amounts of leukemia cells and how MRD results may help doctors assess treatment response, predict relapse risk, and guide important decisions about next steps in care.
Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center where he specializes in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Learn more about Dr. Sallman.
Related Resources
Transcript
Katherine Banwell:
What is measurable residual disease, or MRD? And how is it used in AML care?
Dr. David Sallman:
Yeah. So, this is also extremely important and done through different ways. I draw a very bad iceberg, which is essentially an upside-down triangle, for my patients. And so, I like to say that when we’re looking under the microscope, we’re mid-iceberg. And as the Titanic knows, mid-iceberg’s not so great because what’s beneath?
And so, a lot of our times are to cure the patient. And so, to cure them, I need the whole iceberg away. But we can get closer and closer. So, MRD – we used to say “minimal residual,” and now we say, “measurable residual disease” – based on the technology can tell us in a certain number of cancer cells, are they there or not? So, I’ll just run through kind of the basic ones. Flow cytometry, and specifically an MRD flow cytometry, which is only done at specialized labs.
It’s not done routinely. When you order flow, it’s not MRD flow. This typically gets us between one in 1,000 and one in 10,000 cells, or what is called 0.1 to 0.01 percent, and so pretty good.
But there are testing and are fancy testing for specific gene mutations in particular. These can be PCR approaches or a combination of PCR and next-gen sequencing, where now we can get closer to maybe even down to one in a million cells; if they are positive, we can still see it.
And the reason why that matters, it’s because the real hope – and we’re incorporating it even now as we speak – is that if you become MRD-negative, can we start to avoid things? Can we avoid transplant? Can we stop therapy? Do we think our patient’s cured? Whereas on the flipside, if they’re positive, especially if it’s highly predictive of relapse, then that’s maybe our perfect window to do something then, on or off trial, to improve outcomes.